Zinat Ghanbari; Tahereh Foroughifar; Jayran Zebardast; Samrand Salimi; Saman Tootoonchi; Sara Shabihkhani; Mahnaz Mokhtari Garakani; Tayebeh Forooghifar
Volume 2, Issue 2 , May and June 2017
Abstract
Background: It seems that some herbal medicines such as sage or vitagnus traditionally used as treatment agents are effective on menopausal symptoms such as hot flashes; therefore, the current study aimed at assessing the effect of vitagnus on menopausal symptoms.
Methods: The current study was a ...
Read More
Background: It seems that some herbal medicines such as sage or vitagnus traditionally used as treatment agents are effective on menopausal symptoms such as hot flashes; therefore, the current study aimed at assessing the effect of vitagnus on menopausal symptoms.
Methods: The current study was a prospective clinical trial conducted on 100 menopausal patients divided into 3 groups. In each group, hot flash was treated with vitagnus, sage, or placebo pills and patients were followed-up at the days 15 and 30 after the treat- ment. The data were analyzed by descriptive (percentage, mean, and standard deviation) and inferential (chi-square, t-test, McNa-mara, repeated ANOVA) statistics with SPSS software, version 21 (IBM SPSS, Armonk, NY, USA).
Results: Average of hot flash in vitagnus group was 55.19 ± 14.53; it was also 60.26 ± 14.44 and 60.73 ± 12.30 in the sage and control groups. According to the Cooperman questionnaire score, comparison of hot flash data showed no significant difference between the groups before treatment (the Cooperman questionnaire score < 14) (P = 0.894), (15 - 20) (P = 0.262), (21 - 35) (P = 0.800), (35 < the Cooperman questionnaire score) (P = 0.867). The current study analysis showed no significant difference between the groups in the severity of menopause symptoms at 15-day follow-up (the Cooperman questionnaire score < 14) (P = 0.477), (the Cooperman’s questionnaire score 15 to 20) (P = 0.620), (the Cooperman questionnaire score 21 to 35) (P = 0.243), (35 < the Cooperman questionnaire score) (P = 0.278). But, the severity of menopause symptoms at 30-day follow-up showed significant differences between the groups, except between 15 - 20 and 21 - 35 scores (the Cooperman questionnaire score < 14) (P = 0.306), (15 - 20) (P = 0.005), (21 - 35) (P = 0.007), (35 < the Cooperman questionnaire score) (P = 0.785).
Conclusions: The results of the current study showed that vitagnus and sage were effective on the reduction of menopausal symptoms in postmenopausal females. The effect of placebo on the improvement of menopausal symptoms was significant and it is recommended to be used as an agent to reduce the psychological outcomes of menopause.
Mina Jafarabadi; Fatemeh Ramezanzadeh; Samarand Salimi; Tahereh Forooghifar
Volume 2, Issue 1 , March and April 2017
Abstract
Background: Both in-vitro maturation and in-vitro fertilization have been used successfully to treat females with polycystic ovarian syndrome, who plan to have child. This study compared outcome of these two approaches to fertilize females with polycystic ovary side effects.
Methods: This prospective ...
Read More
Background: Both in-vitro maturation and in-vitro fertilization have been used successfully to treat females with polycystic ovarian syndrome, who plan to have child. This study compared outcome of these two approaches to fertilize females with polycystic ovary side effects.
Methods: This prospective study was conducted at Vali-Asr reproductive health research center and included all females with polycystic ovarian syndrome, who underwent in-vitro maturation or in-vitro fertilization from January 2005 to January 2008. Measurements included demographic data, total cost (including drug and laboratory procedures), outcome (chemical and clinical pregnancy), and systemic complication (ovarian hyper-stimulation syndrome), obtained from the patients’ clinical files. Patients were informed about the procedures, side effects and goals, and the signed consent form for surgical approaches and use of their data in medical research. Finally, these variables were compared between the two groups.
Results: The in-vitro maturation and in-vitro fertilization groups included 20 and 22 patients, respectively. The range of body mass index was between 17.4 and 28.3 kg/m2 and the mean age of the patients was 29.35 ± 4.94 and 28.95 ± 3.84 years, respectively (P > 0.05). The total cost was significantly lower in in-vitro maturation group compared to in-vitro fertilization (201.6 ± 60.1 USD versus 380.5 ± 143.8 USD, respectively, P < 0.001). Positive outcomes were achieved significantly more frequently with the in-vitro fertilization method (1 chemical and no clinical pregnancy in in-vitro maturation versus 7 and 6 in in-vitro fertilization group, respectively, P < 0.001). Although, the rate of ovarian hyper-stimulation syndrome was higher in in-vitro fertilization than in in-vitro maturation approach, yet, it was not statistically significant (P = 0.233).
Conclusions: Our findings showed the superiority of execution of the in-vitro fertilization approach compared with the in-vitro maturation method in infertile females with polycystic ovary syndrome, who planned to have a child. However, in-vitro maturation approach is cheaper than in-vitro fertilization and is also associated with lower risk of ovarian hyper-stimulation syndrome.